Astrazeneca Revenue, Profits - AZN Annual Income Statement

Add to My Stocks
$37.68 $0.04 (0.11%) AZN stock closing price Sep 21, 2018 (Closing)

Fundamental analysis of AZN stock involves analyzing its financial statements, apart from checking the Astrazeneca stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $22.47B for 2017 impacts the AZN stock. Investors typically check year over year or quarter over quarter revenue growth. Revenue for year 2017 is $22.47B and has decreased from $23B year on year as is evident when you compare the latest figures in the latest Astrazeneca profit and loss statement with those of the prior corresponding period. Also see Astrazeneca assets and Astrazeneca free cash flow for a complete valuation of AZN stock.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Astrazeneca Revenues or Net Sales
22.47B23B24.71B26.1B25.71B27.97B33.59B33.27B32.8B31.6B
Cost Of Goods Sold (COGS)4.32B4.13B4.65B5.84B5.26B5.39B6.03B6.39B5.78B6.6B
Astrazeneca Gross Profit
18.15B18.88B20.06B20.25B20.45B22.58B27.57B26.88B27.03B25B
Research & Development Expense5.76B5.89B6B5.58B4.82B5.24B5.52B5.32B4.41B5.18B
Selling General & Admin Expense8.71B8.08B9.95B12.54B11.92B9.19B10.73B10.07B11.08B11.2B
Income Before Depreciation Depletion Amortization3.68B4.9B4.11B2.14B3.71B8.15B11.31B11.49B11.54B8.62B
Depreciation Depletion Amortization----------
Non Operating Income58M34M30M72M50M528M1.06B-517M-736M61M
Interest Expense1.51B1.38B1.08B963M495M958M----
Astrazeneca Pretax Income
2.23B3.55B3.07B1.25B3.27B7.72B12.37B10.98B10.81B8.68B
Provision for Income Taxes-641M146M243M11M696M1.39B2.35B2.9B3.26B2.55B
MinorityInterest-133M-93M1M2M15M30M----
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations2.87B3.41B2.83B1.24B2.57B6.33B10.02B8.08B7.54B6.13B
Extraordinary Items & Discontinued Operations----------
Astrazeneca Profit/ Loss (Net Income)
3B3.5B2.83B1.23B2.56B6.3B10.02B8.08B7.54B6.13B
Average Shares used to compute Diluted EPS1.27B1.27B1.26B2.52B2.51B2.53B2.73B2.89B2.9B2.91B
Average Shares used to compute Basic EPS1.27B1.27B1.26B2.52B2.5B2.52B2.72B2.88B2.9B2.91B
Income Before Nonrecurring Items5.42B5.46B5.39B5.4B6.32B8.66B9.95B8.37B7.54B6.13B
Income from Nonrecurring Items-2.42B-1.96B-2.57B-4.16B-3.76B-2.37B68.05M-293.7M--
Astrazeneca Earnings Per Share Basic Net
2.372.772.230.491.022.503.672.802.602.10
Astrazeneca Earnings Per Share Diluted Net
2.372.762.230.491.022.493.652.792.602.10
EPS Diluted Before Nonrecurring Items4.284.314.262.142.533.433.632.892.602.10
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common1.371.371.381.401.401.431.351.211.050.95
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on Astrazeneca stock analysis. It helps to look at the following income statement items:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Astrazeneca revenue chart implies that the company is growing. It has not been the case with Astrazeneca. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $3B for Astrazeneca for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called statement of revenue and expense. The AZN financials along with Astrazeneca historical stock prices provide a lot of details about the firm.

Astrazeneca Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
19.03
PS Ratio (price sales ratio)
2.14
Operating Margin
14.8
Net Profit Margin
6.8
Dividend Yield
3.64%